Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., added Pablo Rubinstein and Edward Brody to its scientific advisory board.
Anavex Life Sciences Corp., of New York, appointed Michael Gold to its scientific advisory board.
Biodelivery Sciences International Inc., of Raleigh, N.C., appointed David Acheson vice president of sales and managed markets.
Celator Pharmaceuticals Inc., of Ewing, N.J., named Derek Miller chief business officer.
Cytos Biotechnology Ltd., of Zurich, added Yamo Deniz to its board.
Enteris Biopharma Inc., of Boonton, N.J., named Steven J. Brickner, Jonathan Chernoff and Waleed Danho to its scientific advisory board.
Hemispherx Biopharma Inc., of Philadelphia, appointed Thomas Equels chief financial officer and Adam Pascale chief accounting officer.
Medical Marijuana Sciences Inc., part of Nuvilex Inc., of Silver Spring, Md., named Mark L. Rabe chairman of its scientific advisory board.
Melinta Therapeutics Inc., of New Haven, Conn., named Paul Estrem chief financial officer.
Nuevolution A/S, of Copenhagen, Denmark, named Tom Berkien chief business officer.
Qu Biologics Inc., of Vacouver, Britiesh Columbia, named David Mullins chief scientific officer.
Regado Biosciences Inc., of Basking Ridge, N.J., named Michael A. Metzger president and chief operating officer.
Savara Pharmaceuticals Inc., of Austin, Texas, added Joseph S. McCracken and Yuri Pikover to its board.
Scioderm Inc., of Durham, N.C., added John Crowley and William Aliski to its board.
Somalogic Inc., of Boulder, Colo., named Byron Hewett CEO.
Thrombogenics NV, of Leuven, Belgium, appointed Staf Van Reet chairman of the board.
To-BBB Technologies BV, of Leiden, the Netherlands, appointed Carlos de Sousa chief business officer.
Tolera Therapeutics Inc., of Kalamazoo, Mich., named Ashleigh Palmer president and CEO.
Tyrosine Pharma, of Albuquerque, N.M., appointed Wayne Laslie president and CEO.
Valeant Pharmaceuticals International Inc., of Laval, Quebec, appointed Ari Kellen executive vice president/company group chairman, effective Jan. 1, 2014.
Viralytics Ltd., of Sydney, appointed Keith Flaherty to its scientific advisory board.